Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors
Status:
Completed
Trial end date:
2011-07-18
Target enrollment:
Participant gender:
Summary
MEK112111 is a dose-escalation, Phase IB, open-label, single-arm, multi-center study. The
primary objective of the study is to determine the recommended dose and regimen for the
orally administered MEK inhibitor GSK1120212 dosed in combination with gemcitabine in
subjects with solid tumors.